BPC-157, or Body Protecting Compound-157, is a 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from gastric juices.[1][2] It was first identified in the 1990s as part of research into cytoprotective agents that safeguard the gastrointestinal (GI) tract from damage.[3] Unlike many peptides, BPC-157 is highly stable in acidic environments, allowing for oral administration without significant degradation.[4] In compounding pharmacies, BPC-157 is often prepared as capsules, injectables, or topical formulations
SIZE:8.4 oz / 250mL
The process of Lewy body formation, rather than simply -synuclein fibrillization, is one of the major drivers of neurodegeneration
19(8):969-988 Peptide Sequence: Gly-His-Lys(Cu2+) Hong Y, Downey T, Eu KW, Koh PK, Cheah PY (Department f Colorectal Surgery, Singapore General Hospital, Singapore, 169608,Singapore) "A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics" In Clin Exp Metastasis
&srotate=0)
